Literature DB >> 21293058

A microRNA-dependent program controls p53-independent survival and chemosensitivity in human and murine squamous cell carcinoma.

Benjamin Ory1, Matthew R Ramsey, Catherine Wilson, Douangsone D Vadysirisack, Nicole Forster, James W Rocco, S Michael Rothenberg, Leif W Ellisen.   

Abstract

The p53 tumor suppressor, a central mediator of chemosensitivity in normal cells, is functionally inactivated in many human cancers. Therefore, a central challenge in human cancer therapy is the identification of pathways that control tumor cell survival and chemosensitivity in the absence of functional p53. The p53-related transcription factors p63 and p73 exhibit distinct functions—p73 mediates chemosensitivity while p63 promotes proliferation and cell survival—and are both overexpressed in squamous cell carcinomas (SCCs). However, how p63 and p73 interact functionally and govern the balance between prosurvival and proapoptotic programs in SCC remains elusive. Here, we identify a microRNA-dependent mechanism of p63/p73 crosstalk that regulates p53-independent survival of both human and murine SCC. We first discovered that a subset of p63-regulated microRNAs target p73 for inhibition. One of these, miR-193a-5p, expression of which was repressed by p63, was activated by proapoptotic p73 isoforms in both normal cells and tumor cells in vivo. Chemotherapy caused p63/p73-dependent induction of this microRNA, thereby limiting chemosensitivity due to microRNA-mediated feedback inhibition of p73. Importantly, inhibiting miR-193a interrupted this feedback and thereby suppressed tumor cell viability and induced dramatic chemosensitivity both in vitro and in vivo. Thus, we have identified a direct, microRNA-dependent regulatory circuit mediating inducible chemoresistance, whose inhibition may provide a new therapeutic opportunity in p53-deficient tumors.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21293058      PMCID: PMC3026726          DOI: 10.1172/JCI43897

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  50 in total

1.  p63 mediates survival in squamous cell carcinoma by suppression of p73-dependent apoptosis.

Authors:  James W Rocco; Chee-Onn Leong; Nicolas Kuperwasser; Maurice Phillip DeYoung; Leif W Ellisen
Journal:  Cancer Cell       Date:  2006-01       Impact factor: 31.743

2.  Human keratinocytes that express hTERT and also bypass a p16(INK4a)-enforced mechanism that limits life span become immortal yet retain normal growth and differentiation characteristics.

Authors:  M A Dickson; W C Hahn; Y Ino; V Ronfard; J Y Wu; R A Weinberg; D N Louis; F P Li; J G Rheinwald
Journal:  Mol Cell Biol       Date:  2000-02       Impact factor: 4.272

3.  AIS is an oncogene amplified in squamous cell carcinoma.

Authors:  K Hibi; B Trink; M Patturajan; W H Westra; O L Caballero; D E Hill; E A Ratovitski; J Jen; D Sidransky
Journal:  Proc Natl Acad Sci U S A       Date:  2000-05-09       Impact factor: 11.205

4.  Heterozygous germline mutations in the p53 homolog p63 are the cause of EEC syndrome.

Authors:  J Celli; P Duijf; B C Hamel; M Bamshad; B Kramer; A P Smits; R Newbury-Ecob; R C Hennekam; G Van Buggenhout; A van Haeringen; C G Woods; A J van Essen; R de Waal; G Vriend; D A Haber; A Yang; F McKeon; H G Brunner; H van Bokhoven
Journal:  Cell       Date:  1999-10-15       Impact factor: 41.582

Review 5.  On the shoulders of giants: p63, p73 and the rise of p53.

Authors:  Annie Yang; Mourad Kaghad; Daniel Caput; Frank McKeon
Journal:  Trends Genet       Date:  2002-02       Impact factor: 11.639

6.  Oncogenes induce and activate endogenous p73 protein.

Authors:  A Zaika; M Irwin; C Sansome; U M Moll
Journal:  J Biol Chem       Date:  2000-12-13       Impact factor: 5.157

7.  REDD1, a developmentally regulated transcriptional target of p63 and p53, links p63 to regulation of reactive oxygen species.

Authors:  Leif W Ellisen; Kate D Ramsayer; Cory M Johannessen; Annie Yang; Hideyuki Beppu; Karolina Minda; Jonathan D Oliner; Frank McKeon; Daniel A Haber
Journal:  Mol Cell       Date:  2002-11       Impact factor: 17.970

8.  Differential expression of p53 gene family members p63 and p73 in head and neck squamous tumorigenesis.

Authors:  Hong-Ran Choi; John G Batsakis; Feng Zhan; Erich Sturgis; Mario A Luna; Adel K El-Naggar
Journal:  Hum Pathol       Date:  2002-02       Impact factor: 3.466

9.  Role for the p53 homologue p73 in E2F-1-induced apoptosis.

Authors:  M Irwin; M C Marin; A C Phillips; R S Seelan; D I Smith; W Liu; E R Flores; K Y Tsai; T Jacks; K H Vousden; W G Kaelin
Journal:  Nature       Date:  2000-10-05       Impact factor: 49.962

10.  Isoform-specific p73 knockout mice reveal a novel role for delta Np73 in the DNA damage response pathway.

Authors:  Margareta T Wilhelm; Alessandro Rufini; Monica K Wetzel; Katsuya Tsuchihara; Satoshi Inoue; Richard Tomasini; Annick Itie-Youten; Andrew Wakeham; Marie Arsenian-Henriksson; Gerry Melino; David R Kaplan; Freda D Miller; Tak W Mak
Journal:  Genes Dev       Date:  2010-03-01       Impact factor: 11.361

View more
  42 in total

1.  Phospho-ΔNp63α/miR-885-3p axis in tumor cell life and cell death upon cisplatin exposure.

Authors:  Yiping Huang; Alice Y Chuang; Edward A Ratovitski
Journal:  Cell Cycle       Date:  2011-11-15       Impact factor: 4.534

2.  MiR-491-5p negatively regulates cell proliferation and motility by targeting PDGFRA in prostate cancer.

Authors:  Yanjun Xu; Rui Hou; Qijie Lu; Yang Zhang; Lei Chen; Yuanyi Zheng; Bing Hu
Journal:  Am J Cancer Res       Date:  2017-12-01       Impact factor: 6.166

3.  RNA-binding Protein PCBP2 Regulates p73 Expression and p73-dependent Antioxidant Defense.

Authors:  Cong Ren; Jin Zhang; Wensheng Yan; Yanhong Zhang; Xinbin Chen
Journal:  J Biol Chem       Date:  2016-02-23       Impact factor: 5.157

Review 4.  MicroRNA: a third dimension in autophagy.

Authors:  Haiyan Zhai; Andrew Fesler; Jingfang Ju
Journal:  Cell Cycle       Date:  2012-01-15       Impact factor: 4.534

5.  MicroRNA-193 pro-proliferation effects for bone mesenchymal stem cells after low-level laser irradiation treatment through inhibitor of growth family, member 5.

Authors:  Jue Wang; Weicong Huang; Yihe Wu; Jianfeng Hou; Yu Nie; Haiyong Gu; Jun Li; Shengshou Hu; Hao Zhang
Journal:  Stem Cells Dev       Date:  2012-04-20       Impact factor: 3.272

6.  Glyceollins as novel targeted therapeutic for the treatment of triple-negative breast cancer.

Authors:  Lyndsay V Rhodes; Syreeta L Tilghman; Stephen M Boue; Shuchun Wang; Hafez Khalili; Shannon E Muir; Melyssa R Bratton; Qiang Zhang; Guangdi Wang; Matthew E Burow; Bridgette M Collins-Burow
Journal:  Oncol Lett       Date:  2011-10-24       Impact factor: 2.967

7.  ΔNp63α Silences a miRNA Program to Aberrantly Initiate a Wound-Healing Program That Promotes TGFβ-Induced Metastasis.

Authors:  Lidia Rodriguez Calleja; Camille Jacques; François Lamoureux; Marc Baud'huin; Marta Tellez Gabriel; Thibaut Quillard; Debashish Sahay; Pierre Perrot; Jerome Amiaud; Celine Charrier; Regis Brion; Fernando Lecanda; Franck Verrecchia; Dominique Heymann; Leif W Ellisen; Benjamin Ory
Journal:  Cancer Res       Date:  2016-03-17       Impact factor: 12.701

8.  Disruption of TP63-miR-27a* Feedback Loop by Mutant TP53 in Head and Neck Cancer.

Authors:  Nikhil S Chari; Cristina Ivan; Xiandong Le; Jinzhong Li; Ainiwaer Mijiti; Ameeta A Patel; Abdullah A Osman; Christine B Peterson; Michelle D Williams; Curtis R Pickering; Carlos Caulin; Jeffrey N Myers; George A Calin; Stephen Y Lai
Journal:  J Natl Cancer Inst       Date:  2020-03-01       Impact factor: 13.506

9.  Downregulation of miR-193a-5p correlates with lymph node metastasis and poor prognosis in colorectal cancer.

Authors:  Peng Zhang; Deng-Bo Ji; Hai-Bo Han; Yun-Fei Shi; Chang-Zheng Du; Jin Gu
Journal:  World J Gastroenterol       Date:  2014-09-14       Impact factor: 5.742

10.  FGFR2 signaling underlies p63 oncogenic function in squamous cell carcinoma.

Authors:  Matthew R Ramsey; Catherine Wilson; Benjamin Ory; S Michael Rothenberg; William Faquin; Alea A Mills; Leif W Ellisen
Journal:  J Clin Invest       Date:  2013-07-08       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.